GTC Biotherapeutics, the Framingham, MA-based company that won FDA approval for the first drug manufactured in genetically modified animals, has cut 50 jobs in connection with a new $7 million convertible debt financing round. The company’s CEO, Geoffrey Cox and “several other members of the current senior management team” will be leaving the company, according to a statement. William Heiden, the former CEO of Elixir Pharmaceuticals, is replacing Cox as the new leader of GTC.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
